Michael Heartlein Net Worth

Michael Heartlein biography

DR. Michael W. Heartlein Ph.D. serves as Founder, Executive Vice President of the Company. Dr. Heartlein joined Translate Bio in 2016. He has been in research and development since 1989, when he joined the founding team of scientists at TKT (Shire acquired TKT in 2005). Prior to his current role, Mike was head of messenger RNA therapeutics at Shire. Mike’s career in R&D has focused on the discovery and development of platform technologies, product discovery and product development. He began with the development of nonviral ex-vivo gene therapy and is an inventor on 16 issued U.S. patents covering this technology. Mike also co-invented and developed Gene Activation technology, FGE-sulfatase technology and Shire’s human cell protein production platform. He discovered and developed gene-activated erythropoietin (Dynepo®), the first human cell–produced erythropoietin, approved in Europe in 2002. Mike discovered and led early development of Shire’s enzyme replacement therapies for Fabry disease (Replagal®) and Gaucher disease (Vpriv®) and early development of Elaprase® for Hunter syndrome. He also led the teams responsible for the discovery and nonclinical development of Shire’s intrathecal CNS enzyme replacement therapies currently in clinical development. Most recently, Mike discovered and developed Shire's Messenger RNA Therapy (MRT) technology acquired by Translate Bio (formerly RaNA Therapeutics). Prior to joining Shire, Mike held a hospital appointment in genetics at Children's Hospital Boston and a faculty appointment in pediatrics at Harvard Medical School. Mike received his PhD in Genetics from Oak Ridge National Laboratory – University of Tennessee. He has over 30 scientific publications, 39 issued US patents and over 60 pending US patent applications.

How old is Michael Heartlein?

Michael Heartlein is 60, he's been the Founder e Executive Vice President of Telesis Bio Inc since 2019. There are 4 older and 9 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.

What's Michael Heartlein's mailing address?

Michael's mailing address filed with the SEC is C/O TRANSLATE BIO, INC., 29 HARTWELL AVE, LEXINGTON, MA, 02421.

Insiders trading at Telesis Bio Inc

Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk e Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.

What does Telesis Bio Inc do?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Telesis Bio Inc executives and stock owners

Telesis Bio Inc executives and other stock owners filed with the SEC include:

• Ronald Renaud,
  President, Chief Executive Officer, Director
• Richard Wooster,
  Chief Scientific Officer
• John Schroer,
  Chief Financial Officer, Treasurer
• Brian Fenton,
  Chief Business Officer
• Robert Plenge,
  Independent Director
• Robert Meyer,
  Independent Director
• George Demetri,
  Independent Director
• Daniel Lynch,
  Independent Chairman of the Board
• Daniella Beckman,
  Independent Director
• Owen Hughes,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Ann Barbier,
  Chief Medical Officer
• Frank DeRosa,
  Chief Technology Officer
• Paula Cloghessy,
  Chief Human Resource Officer
• Paul Burgess,
  Chief Operating Officer, Chief Legal Officer
• Michael Heartlein,
  Founder, Executive Vice President
• Paul M Meister,
  Director
• Everett Rand Sutherland,
  President
• Brian M. Jr. Gallagher,
  Director
• Ventures Fund Llc Mrl,
  10% owner
• Venture Fund Viii, L.P.Atla...,
  
• Plc Gsk,
  10% owner
• Human Genetic Therapies, In...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• James B Weissman,
  
• Michael R. Hodges,
  
• Todd Krueger,
  
• Steven J Golub,
  
• Sarah E. Hlavinka,
  
• Daniel Glenn Gibson,
  Chief Technology Officer
• Human Genetic Therapies, In...,
  
• Group Llc/Ma Baupost Group ...,
  
• Brendan Smith,
  Chief Financial Officer
• Sanofi,
  10% owner
• Ventures Gp, Llc Northpond ...,
  
• Fund Iv, Llc Broad Oak,
  10% owner
• William Snider,
  Director
• William J Kullback,
  Chief Financial Officer
• Rob Cutler,
  Chief Legal Officer
• Todd Robert Nelson,
  Chief Executive Officer
• Eric Eugene Esser,
  President & CEO
• Frank Witney,
  
• Christine A Tsingos,
  
• Annette Tumolo,
  
• Gregory J. Herrema,
  
• Jami K Nachtsheim,